B-Tg(hEGFR) MC38|BioMice百奥动物

Common name	B-Tg(hEGFR) MC38	Catalog number	322295
Aliases	EGFR, ERBB, ERBB1, ERRP, HER1, NISBD2, PIG61, mENA, epidermal growth factor receptor	Disease	Colon carcinoma
Organism	Mouse	Strain	C57BL/6
Tissue types	Colon	Tissue	Colon

模型验证

Description

Origin: The MC38 cell line is derived from C57BL6 murine colon adenocarcinoma cells. The cell line is a commonly used murine model for colorectal carcinoma.
Background Information: The epidermal growth factor receptor (EGFR/Erbb1) belongs to a family of structurally related tyrosine kinase receptors, including Erbb2/neu, Erbb3 and Erbb4, which upon ligand binding can form homo- and heterodimers. Several growth factors such as epidermal growth factor (EGF), transforming growth factor α (TGFα), amphiregulin, heparin binding EGF (HB-EGF), β-cellulin and epiregulin can bind the EGFR and induce receptor dimerisation. Subsequent activation of the intrinsic tyrosine kinase induces complex downstream signalling pathways, which can instruct cells either to proliferate, differentiate and/or survive. Also, it has been shown that many cancer cells are characterized by EGFR hyperactivation, overexpression, or mutants with dysregulated signaling. These EGFR-dependent perturbations are also correlated with poor patient prognosis. Consequently, EGFR and its signaling activity have been targets for developing novel therapeutic drugs to treat a variety of cancers.
Gene targeting strategy: The expression cassette containing an exogenous promoter, the extracellular region of human EGFR, and the transmembrane and intracellular regions of mouse Egfr was randomly inserted into the genome of B-Tg(hEGFR) MC38 cells.
Tumorigenicity: Confirmed in B-hEGFR mice and B-h4-1BB/hEGFR mice.
Application: The B-Tg(hEGFR) MC38 tumor models can be used for preclinical evaluation of The B-Tg(hEGFR) MC38 tumor models can be used for preclinical evaluation of anti-human EGFR antibodies.
Notes:

B-Tg(hEGFR) MC38 #1-E02 can not establish tumors in wild-type C57BL/6 mice, and only in EGFR related humanized mice.
B-Tg(hEGFR) MC38 cells simultaneously express humanized EGFR and EGFP. If detecting the expression of humanized EGFR, it is necessary to choose an appropriate flow channel.

Protein expression analysis

EGFR expression analysis in B-Tg(hEGFR) MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-Tg(hEGFR) MC38 cultures were stained with species-specific anti-EGFR antibody. Human EGFR was detected on the surface of B-Tg(hEGFR) MC38 cells but not wild-type MC38 cells. The 1-E02 clone of B-Tg(hEGFR) MC38 cells was used for in vivo tumor growth assays.

Tumor growth curve & body weight changes

Subcutaneous tumor growth of B-Tg(hEGFR) MC38 cells. B-Tg(hEGFR) MC38 cells (5x10⁵) and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into homozygous B-hEGFR mice (female, 6-9 weeks-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume. (B) Body weight. Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter². Results indicate that B-Tg(hEGFR) MC38 cells were able to establish tumors in vivo and can be used for efficacy studies. Values are expressed as mean ± SEM.

Protein expression analysis of tumor tissue

EGFR expression evaluated on B-Tg(hEGFR) MC38 tumor cells by flow cytometry. B-Tg(hEGFR) MC38 cells were subcutaneously transplanted into homozygous B-hEGFR mice (n=6). Upon conclusion of the experiment, tumor cells were harvested and analyzed with anti-human EGFR antibody by flow cytometry. As shown, human EGFR was highly expressed on the surface of tumor cells. Therefore, B-Tg(hEGFR) MC38 cells can be used for in vivo efficacy studies evaluating novel EGFR therapeutics.

Tumor growth curve & body weight changes

Subcutaneous tumor growth of B-Tg(hEGFR) MC38 cells. B-Tg(hEGFR) MC38 cells (5x10⁵, 1x10⁶) and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into homozygous B-hEGFR mice (female, 5-8 weeks-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume. (B) Body weight. Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². Results indicate that B-Tg(hEGFR) MC38 cells were able to establish tumors in vivo and can be used for efficacy studies. Values are expressed as mean ± SEM.

Tumor growth curve & body weight changes

Subcutaneous tumor growth of B-Tg(hEGFR) MC38 cells. B-Tg(hEGFR) MC38 cells (5x10⁵) and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into heterozygous B-h4-1BB/hEGFR mice (male, 6 weeks-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume. (B) Body weight. Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². Results indicate that B-Tg(hEGFR) MC38 cells were able to establish tumors in vivo and can be used for efficacy studies. Values are expressed as mean ± SEM.

In vivo efficacy of anti-human EGFR antibodies

Antitumor activity of anti-human EGFR antibody in B-Tg(hEGFR) mice. (A) Anti-human EGFR antibody inhibited B-Tg(hEGFR) MC38 tumor growth in homozygous B-hEGFR mice. Murine colon cancer B-Tg(hEGFR) MC38 cells were subcutaneously implanted into homozygous B-hEGFR mice (female, 6-8 weeks-old, n=6). Mice were grouped when tumor volume reached approximately 50-150 mm³, at which time they were intravenous injected with anti-human EGFR ADC cetuximab analog-MMAE (in house) indicated in panel. (B) Body weight changes during treatment. As shown in panel A, 30mg/kg anti-human EGFR ADC cetuximab analog-MMAE (in house) treatment group was efficacious in controlling tumor growth in B-hEGFR mice, demonstrating that the B-Tg(hEGFR) MC38 provide a powerful preclinical model for in vivo evaluation of anti-human EGFR antibodies. Values are expressed as mean ± SEM.

In vivo efficacy of anti-human EGFR antibodies-individual tumor growth curves

Antitumor activity of anti-human EGFR antibody in B-Tg(hEGFR) mice. Anti-human EGFR antibody inhibited B-Tg(hEGFR) MC38 tumor growth in homozygous B-hEGFR mice. Murine colon cancer B-Tg(hEGFR) MC38 cells were subcutaneously implanted into homozygous B-hEGFR mice (female, 6-8 weeks-old, n=6). Mice were grouped when tumor volume reached approximately 50-150 mm³, at which time they were intravenous injected with anti-human EGFR ADC cetuximab analog-MMAE (in house) indicated in panel.